Evidence map›Paper›PMID 34362358›Full record

ArticleBMC veterinary research2021

Donkey-derived anti-CDV IgG, as a passive immunotherapy agent, can effectively increase survival rates of the experimental CDV-infected dogs.

Jianlou Zhang, Dan Cui, Yuzhu Zuo, Zhiqiang Zheng, Fengyang Wu, Wenyan Li, Yonghong Zhang, Shanshan Huo, Nan Li, Lanhui Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jianlou Zhang *School of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Dan Cui *School of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Yuzhu Zuo *School of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Zhiqiang ZhengSchool of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Fengyang WuSchool of Animal Science and Technology, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Wenyan LiSchool of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Yonghong ZhangSchool of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Shanshan HuoSchool of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Nan LiSchool of Animal Science and Technology, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Lanhui LiSchool of Animal Science and Technology, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China.
Yueqiang GuanSchool of Life Science, Hebei University, 180 Wusi East Road, Baoding, 071002, Hebei, China. guanyueqiang@hbu.edu.cn.
Fei ZhongSchool of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China. zhongf@hebau.edu.cn.
Hebei Agricultural University · CNHebei University · CN

Funding

National Key Research Project 2016YFD0501002Natural Science Foundation of Hebei) C2013204130
6 · The paper itself

Abstract

backgroundHumoral immunity plays an important role in the prevention of canine distemper. Anti-CD virus (CDV) antibody has strong antiviral activity and is widely used in the treatment of CD. However, with the increase of CD cases, the availability of therapeutic CD antibody fell short of the clinical needs.

resultsThe high-titer antiserum with the high-titer neutralizing activity against CDV was obtained from the donkeys (Dezhou Donkey) immunized with the inactivated CDV vaccine. The donkey anti-CDV IgG was purified from the donkey serum, which was identified to significantly inhibit the CDV replication in the cultured Vero cells and effectively reduce the clinical symptoms and increase the survival rates (75%) of CDV-infected dogs (Shih-tzu Dog), similar to that treated with the dog-derived anti-CDV IgG. These results indicate that donkey-derived IgG is a potential substitute for dog-derived IgG to treat the CD in clinic.

conclusionsAdministration of donkey-derived anti-CDV IgG can ameliorate clinical symptoms and inhibit virus replication, thereby increasing the survival of CDV-infected dogs. This study opens up a new source of therapeutic antibody for CD treatment.

Indexed as

AnimalsAntibodies, ViralDistemperDistemper Virus, CanineDogsEquidaeImmune SeraImmunization, PassiveImmunoglobulin GSurvival RateVirus ReplicationAntibodies, ViralImmune SeraImmunoglobulin GCanine distemper virusDonkeyHeterologous antibodyPassive immunotherapyTherapeutic effects

Identifiers

PMID34362358
PMCPMC8344326
OpenAlexW3187408483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.